Biohit Oyj of Helsinki at MEDICA 2021 in Düsseldorf -- MEDICA - World Forum for Medicine
Manage stand orders
Select Option

Biohit Oyj

Laippatie 1, 00880 Helsinki

Submit your contact details

Provide your contact details to the exhibitor. Optionally, you may also add a personal message.

Please log in

You must be logged in to send the contact request.

An error has occurred

Please check your internet connection or try again later.

Message has been sent

Your message to the exhibitor was sent successfully.

This company is co-exhibitor of
Wulff Entre Ltd.

Hall map

MEDICA 2021 hall map (Hall 1): stand A15

Fairground map

MEDICA 2021 fairground map: Hall 1


Ilari Patrakka

Sales and Marketing Director



Please log in

You must be logged in to use matchmaking

Please log in for matchmaking

Registration is required to use the networking service and a separate registration for matchmaking. Please register for Matchmaking first.

Let's get started!

Welcome to Matchmaking. Would you like to get in touch with ?

Our range of products

Product categories

  • 03  Diagnostic tests
  • 03.04  Microbiology testing
  • 03.04.03  Rapid tests in microbiology

Rapid tests in microbiology

Our products

Product category: Rapid tests in microbiology

Now available new GastroPanel Quick test

GastroPanel Quick test, immunological lateral-flow test for detecting GastroPanel biomarkers:

·  Finds patients with a healthy stomach

·  Detects reliably gastritis and H. pylori infection

·  Detects the often asymptomatic atrophic gastritis

·  Gives information about gastric acid output

·  Discloses the subjects at increased risk of gastric cancer and peptic ulcer

More Less

About us

Company portrait

Biohit Oyj is a Finnish biotechnology company operating on global markets. Our mission, “Innovating for Health”, describes our innovative products and services, which aim to promote medical research and early diagnosis, and prevent serious illnesses.

Our goal is to improve people’s quality of life by preventing diseases, human suffering and financial loss. Biohit is headquartered in Helsinki and has subsidiaries located in Italy and the United Kingdom. Biohit’s Series B shares (BIOBV) are listed in Nasdaq OMX Helsinki Small Cap group and in the healthcare sub-sector. More information about the share and financials is available in the Investors section of this site.

Biohit serves healthcare organisations and patients by promoting gastric and colorectal health. The most recent innovation is Acetium®, which promotes smoking cessation.

Cost-effective innovations for healthcare
Gastrointestinal diseases are a growing world-wide concern, with related medical, ethical and financial problems. World-wide, gastrointestinal diseases are the most common cause for people to seek treatment or suffer problems due to a lack of treatment. As the population ages, the need for healthcare will increase further, leading to an urgent requirement for new, cost-effective solutions.

The numerous health-related problems caused by smoking are the most common preventable form of mortality in western countries. Biohit helps people to give up smoking with a new method that does not cause nicotine addiction. The Acetium® lozenge is a natural preparation containing L cysteine which has already helped numerous smokers to stop smoking altogether or significantly reduce their smoking.

Biohit continuously develops its products and services to address society’s needs. Our products and services are researched, cost-effective innovations for diagnosing and preventing diseases and associated risks.

Innovations and patents
Biohit’s operations are based on a goal-oriented and long-term innovation and patenting strategy. Biohit works with scientific communities to produce new technologies, products and services based on research results and innovations that can be used to develop safe and cost-effective diagnostic tests for the early detection and prevention of diseases of the gastrointestinal tract.